Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 138
Filter
1.
Article in English | MEDLINE | ID: mdl-31826986

ABSTRACT

OBJECTIVE: The use of alemtuzumab, a humanized monoclonal anti-CD52 antibody has changed the therapy of highly active relapsing-remitting MS (RRMS). Alemtuzumab infusion depletes most lymphocytes in peripheral blood, whereas differential recovery of immune cells, probably those with a less CNS-autoreactive phenotype, is supposed to underlie its long-lasting effects. To determine whether alemtuzumab significantly reduces immunoglobulin levels in blood and CSF of treated patients, we analyzed blood and CSF samples of 38 patients with MS treated with alemtuzumab regarding changes in immunoglobulin levels. METHODS: Blood and CSF samples of patients were collected at the beginning of alemtuzumab treatment and at 12, 24, and 36 months after the first administration of the drug. Specimens were analyzed regarding immunoglobulin concentrations in blood and CSF. RESULTS: We observed significant and dose-dependent reductions of immunoglobulin levels (IgG, IgM, and IgA) in serum and CSF 12 and 24 months following 2 courses of alemtuzumab. Patients with persistent or returning disease activity who were treated with a third course of alemtuzumab exhibited even further decrease in IgG levels compared with matched controls treated twice. Here, alemtuzumab-treated patients with IgG levels below the lower limits of normal were more susceptible to pneumonia, sinusitis, and otitis, whereas upper respiratory tract and urinary tract infections were not associated therewith. CONCLUSIONS: Our results suggest to monitor IgG levels for safety reasons in patients treated with alemtuzumab-in particular when additional treatment courses are required-and to consider preventive action in critical cases. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that for patients with RRMS alemtuzumab reduces immunoglobulin levels.


Subject(s)
Alemtuzumab/pharmacology , Immunoglobulin G/drug effects , Immunologic Factors/pharmacology , Multiple Sclerosis, Relapsing-Remitting/drug therapy , Multiple Sclerosis, Relapsing-Remitting/immunology , Adolescent , Adult , Alemtuzumab/administration & dosage , Female , Follow-Up Studies , Humans , Immunoglobulin A/blood , Immunoglobulin A/cerebrospinal fluid , Immunoglobulin A/drug effects , Immunoglobulin G/blood , Immunoglobulin G/cerebrospinal fluid , Immunoglobulin M/blood , Immunoglobulin M/cerebrospinal fluid , Immunoglobulin M/drug effects , Immunologic Factors/administration & dosage , Male , Middle Aged , Multiple Sclerosis, Relapsing-Remitting/blood , Multiple Sclerosis, Relapsing-Remitting/cerebrospinal fluid , Young Adult
2.
ACS Nano ; 13(8): 9315-9324, 2019 08 27.
Article in English | MEDLINE | ID: mdl-31348638

ABSTRACT

Polyethylene glycol (PEG)-coated nanopharmaceuticals can cause mild to severe hypersensitivity reactions (HSRs), which can occasionally be life threatening or even lethal. The phenomenon represents an unsolved immune barrier to the use of these drugs, yet its mechanism is poorly understood. This study showed that a single i.v. injection in pigs of a low dose of PEGylated liposomes (Doxebo) induced a massive rise of anti-PEG IgM in blood, peaking at days 7-9 and declining over 6 weeks. Bolus injections of PEG-liposomes during seroconversion resulted in anaphylactoid shock (pseudo-anaphylaxis) within 2-3 min, although similar treatments of naïve animals led to only mild hemodynamic disturbance. Parallel measurement of pulmonary arterial pressure (PAP) and sC5b-9 in blood, taken as measures of HSR and complement activation, respectively, showed a concordant rise of the two variables within 3 min and a decline within 15 min, suggesting a causal relationship between complement activation and pulmonary hypertension. We also observed a rapid decline of anti-PEG IgM in the blood within minutes, increased binding of PEGylated liposomes to IgM+ B cells in the spleen of immunized animals compared to control, and increased C3 conversion by PEGylated liposomes in the serum of immunized pigs. These observations taken together suggest rapid binding of anti-PEG IgM to PEGylated liposomes, leading to complement activation via the classical pathway, entailing anaphylactoid shock and accelerated blood clearance of liposome-IgM complexes. These data suggest that complement activation plays a causal role in severe HSRs to PEGylated nanomedicines and that pigs can be used as a hazard identification model to assess the risk of HSRs in preclinical safety studies.


Subject(s)
Anaphylaxis/immunology , Complement Activation/immunology , Polyethylene Glycols/adverse effects , Polyethylene Glycols/pharmacology , Anaphylaxis/pathology , Animals , Antibodies, Anti-Idiotypic/immunology , B-Lymphocytes/drug effects , B-Lymphocytes/immunology , Humans , Immunoglobulin M/drug effects , Immunoglobulin M/immunology , Liposomes/adverse effects , Liposomes/chemistry , Liposomes/immunology , Liposomes/pharmacology , Polyethylene Glycols/chemistry , Spleen/drug effects , Spleen/immunology , Swine
3.
Cancer Res ; 79(1): 159-170, 2019 01 01.
Article in English | MEDLINE | ID: mdl-30224373

ABSTRACT

Metastatic cancer involving spread to the peritoneal cavity is referred to as peritoneal carcinomatosis and has a very poor prognosis. Activating the antitumor immune response in the characteristically immune-suppressive peritoneal environment presents a potential strategy to treat this disease. In this study, we show that a toll-like receptor (TLR) and C-type lectin receptor (CLR) agonist pairing of monophosphoryl lipid A (MPL) and trehalose-6,6'-dicorynomycolate (TDCM) effectively inhibits tumor growth and ascites development in a mouse model of aggressive mammary cancer-induced peritoneal carcinomatosis. MPL/TDCM treatment similarly inhibited peritoneal EL4 tumor growth and ascites development. These effects were not observed in mice lacking B cells or mice lacking CD19, which are deficient in B-1a cells, an innate-like B-cell population enriched in the peritoneal cavity. Remarkably, adoptive transfer of B-1a cells, but not splenic B cells from WT mice, restored MPL/TDCM-induced protection in mice with B-cell defects. Treatment induced B-1 cells to rapidly produce high levels of natural IgM reactive against tumor-associated carbohydrate antigens. Consistent with this, we found significant deposition of IgM and C3 on peritoneal tumor cells as early as 5 days post-treatment. Mice unable to secrete IgM or complement component C4 were not protected by MPL/TDCM treatment, indicating tumor killing was mediated by activation of the classical complement pathway. Collectively, our findings reveal an unsuspected role for B-1 cell-produced natural IgM in providing protection against tumor growth in the peritoneal cavity, thereby highlighting potential opportunities to develop novel therapeutic strategies for the prevention and treatment of peritoneal metastases. SIGNIFICANCE: This work identifies a critical antitumor role for innate-like B cells localized within the peritoneal cavity and demonstrates a novel strategy to activate their tumor-killing potential.See related commentary by Tripodo, p. 5.


Subject(s)
B-Lymphocyte Subsets/immunology , Immunity, Innate/immunology , Immunoglobulin M/immunology , Lymphocyte Activation/immunology , Mammary Neoplasms, Animal/immunology , Peritoneal Cavity/pathology , Peritoneal Neoplasms/immunology , Animals , B-Lymphocyte Subsets/drug effects , B-Lymphocyte Subsets/metabolism , B-Lymphocyte Subsets/pathology , Cord Factors/pharmacology , Female , Immunity, Innate/drug effects , Immunoglobulin M/drug effects , Lectins, C-Type/agonists , Lipid A/analogs & derivatives , Lipid A/pharmacology , Lymphocyte Activation/drug effects , Male , Mammary Neoplasms, Animal/drug therapy , Mammary Neoplasms, Animal/metabolism , Mammary Neoplasms, Animal/pathology , Mice , Mice, Inbred A , Mice, Inbred C57BL , Peritoneal Neoplasms/drug therapy , Peritoneal Neoplasms/metabolism , Peritoneal Neoplasms/secondary , Toll-Like Receptors/agonists
4.
Clin Exp Immunol ; 194(3): 391-399, 2018 12.
Article in English | MEDLINE | ID: mdl-30136282

ABSTRACT

Rheumatoid arthritis (RA) is a chronic inflammatory disease where serum analysis of anti-citrullinated peptide/protein antibodies (ACPA) is an important diagnostic/prognostic tool. Levels and changes of ACPA in RA patients have been studied previously in relation to disease course and therapy response, but less is known regarding ACPA isotype changes in early RA. Hence, recent-onset RA patients (n = 231) were subjected to a 3-year clinical and radiological follow-up. Serum samples were serially collected and ACPA isotypes were analysed using the second-generation cyclic citrullinated peptide (CCP) as capture antigen. Changes in ACPA isotype levels and status were related to disease course and pharmacotherapy. At inclusion, 74% of the patients tested positive for ACPA IgG; 55% for immunoglobulin (Ig)A, 37% for secretory IgA (SIgA) and 35% for IgM. The proportion of positive patients decreased significantly at follow-up regarding ACPA SIgA, IgM and IgA. During the initial 3 months, reduction of the 28-joint disease activity score (DAS28) correlated with reduced levels of ACPA IgG (Rho = 0·242, P = 0·003), IgA (Rho = 0·260, P = 0·008), IgM (Rho = 0·457, P < 0·001) and SIgA (Rho = 0·402, P < 0·001). Levels of ACPA SIgA (P = 0·008) and IgM (P = 0·021) decreased significantly among patients with good response to treatment, which was not seen regarding ACPA IgA or IgG. Changes in ACPA isotype levels were not associated with radiographic damage. In conclusion, ACPA SIgA and IgM declined rapidly upon anti-rheumatic therapy and correlated with decreased disease activity in recent-onset RA. This may indicate that down-regulation of mucosal immunity to citrullinated proteins/peptides and recruitment of new B cells are key features of therapy responses in early RA.


Subject(s)
Arthritis, Rheumatoid/immunology , Autoantibodies/blood , Immunoglobulin A, Secretory/blood , Immunoglobulin G/blood , Immunoglobulin M/blood , Peptides, Cyclic/immunology , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Autoantibodies/immunology , Disease Progression , Female , Humans , Immunoglobulin A, Secretory/drug effects , Immunoglobulin A, Secretory/immunology , Immunoglobulin G/immunology , Immunoglobulin M/drug effects , Immunoglobulin M/immunology , Longitudinal Studies , Male , Middle Aged , Surveys and Questionnaires
5.
Acta Odontol Scand ; 76(5): 351-356, 2018 Jul.
Article in English | MEDLINE | ID: mdl-29648491

ABSTRACT

OBJECTIVE: The oral mucosa of patients undergoing dental procedures is often exposed to residual monomers leaking from incompletely cured acrylic resins. We investigated whether 2-hydroxyethyl methacrylate (HEMA) monomers applied to the sublingual mucosa in mice modulate the antibody responses towards co-administered ovalbumin (OVA) or live oral bacteria. MATERIAL AND METHODS: OVA, live mouse oral commensal Lactobacillus murinus or live human oral commensal Streptococcus mutans were administered sublingually with or without HEMA to BALB/c mice on four weekly occasions. One week after the last administration, the experiment was terminated and serum antibody levels were analyzed using ELISA. RESULTS: Significantly increased IgG and IgE anti-OVA antibody activity was found in the sera from mice immunized with OVA together with HEMA, as compared to mice immunized with OVA alone. Likewise, S. mutans together with HEMA induced an IgG anti-S. mutans antibody response that was significantly higher than the antibody response detected after application of S. mutans alone. No IgG anti-L. murinus antibody response was detected in mice immunized with L. murinus together with HEMA, as compared to the background activity. CONCLUSIONS: We report that HEMA monomers have adjuvant properties when sublingually administered in combination with OVA or S. mutans.


Subject(s)
Dental Materials/pharmacology , Immunoglobulin G/drug effects , Immunoglobulin M/drug effects , Methacrylates/pharmacology , Ovalbumin/immunology , Administration, Sublingual , Animals , Antibody Formation , Enzyme-Linked Immunosorbent Assay , Female , Humans , Mice , Mice, Inbred BALB C , Streptococcus mutans/metabolism
6.
Transplant Proc ; 49(6): 1483-1491, 2017.
Article in English | MEDLINE | ID: mdl-28736027

ABSTRACT

BACKGROUND: Delayed xenograft rejection (DXR) is an insurmountable barrier for xenotransplantation. Previous studies reported that hamster hearts transplanted into rats undergo DXR and stop functioning after the cessation of immunosuppression. Herein, we investigated the effects of resveratrol on preventing DXR in a hamster-to-rat vascularized cardiac xenograft model. METHODS: Hamster hearts were engrafted into Lewis rat recipients. Recipient rats received a graft acceptance-inducing treatment of leflunomide and FK506 for 2 weeks to prevent acute xenograft rejection (AXR). Then, all recipient rats were randomly divided into two groups: one group was treated with 1% carboxymethyl cellulose vehicle (control group) and one group was treated with resveratrol (RES group). RESULTS: After cessation of FK506 and Lef in recipient rats, treatment with resveratrol prolonged the mean survival time from 8.5 days in the control group to 23.5 days. Compared with the control group, neutrophil infiltration in both cardiac muscle and blood vessel tissues of the grafts after resveratrol treatment was significantly reduced. Meanwhile, resveratrol treatment also significantly inhibited T-cell response along with increased production of cytokines including interleukin (IL)-4, IL-10, and decreased interferon (IFN)-gamma of recipients. Furthermore, in the RES group, immunoglobulin (Ig)M antibody production was markedly inhibited, while the production of IgG antibody and the frequency of B cells did not vary. CONCLUSION: Administration of resveratrol can markedly delay the emergence of DXR by inhibiting IgM secretion.


Subject(s)
Delayed Graft Function/prevention & control , Graft Rejection/prevention & control , Heart Transplantation/methods , Stilbenes/therapeutic use , Transplantation, Heterologous/methods , Animals , Antioxidants/therapeutic use , Cricetinae , Heterografts/drug effects , Immunoglobulin M/drug effects , Isoxazoles/therapeutic use , Leflunomide , Male , Rats , Rats, Inbred Lew , Resveratrol , T-Lymphocytes/drug effects , Tacrolimus/therapeutic use
8.
Oncotarget ; 8(3): 4703-4717, 2017 Jan 17.
Article in English | MEDLINE | ID: mdl-28002795

ABSTRACT

At present, very limited studies focus on the toxic effect of sodium fluoride (NaF) on splenic development of human and animals in vivo. This study was firstly designed to evaluate the toxic effects of NaF on the splenic development of mice in vivo by observing histopathological lesions, changes of splenic growth index (GI), T and B cells, immunoglobulin A (IgA), immunoglobulin G (IgG) and immunoglobulin M (IgM) contents, cytokine protein expression levels, and cell cycle and cyclins/cdks protein expression levels using the methods of pathology, flow cytometry (FCM), western blot (WB), and enzyme-linked immunosorbent assay (ELISA). A total of 240 ICR mice were equally allocated into four groups with intragastric administration of distilled water in the control group and 12, 24, 48 mg/kg NaF solution in the experimental groups for 42 days. The results showed that NaF in 12 mg/kg and over caused the toxic effects on splenic development, which was characterized by reducing growth index and lymphocytes in the white and red pulp histopathologically, increasing cell percentages of the G0/G1 phase and decreasing cell percentages of the S phase, and reducing T cells and B cells as well as IgA, IgG, and IgM contents when compared with those in the control group. Concurrently, cytokines including interleukin-2 (IL-2), transforming growth factor beta (TGF-ß), tumor necrosis factor alpha (TNF-α), interferon gamma (IFN-γ) and cyclin (E/D and CDK2/4) protein expression levels were markedly decreased (P < 0.05 or P < 0.01), and interleukin-10 (IL-10) protein expression levels were significantly increased (P < 0.05 and P < 0.01) in the three NaF-treated groups. Toxic effects finally impaired the splenic cellular immunity and humoral immunity due to the reduction of T and B cell population and activity. Cell cycle arrest is the molecular basis of NaF-caused toxic effects on the splenic development.


Subject(s)
Cell Cycle/drug effects , Sodium Fluoride/toxicity , Spleen/growth & development , Spleen/immunology , Animals , B-Lymphocytes/drug effects , Cell Cycle Proteins/metabolism , Cytokines/metabolism , Gene Expression Regulation, Developmental/drug effects , Immunoglobulin A/drug effects , Immunoglobulin G/drug effects , Immunoglobulin M/drug effects , Mice , Mice, Inbred ICR , Spleen/drug effects , T-Lymphocytes/drug effects , Toxicity Tests
9.
Toxicol Appl Pharmacol ; 304: 79-89, 2016 08 01.
Article in English | MEDLINE | ID: mdl-27221630

ABSTRACT

Geogenic dust from arid environments is a possible inhalation hazard for humans, especially when using off-road vehicles that generate significant dust. This study focused on immunotoxicological and neurotoxicological effects following subacute exposure to geogenic dust generated from sediments in the Nellis Dunes Recreation Area near Las Vegas, Nevada that are particularly high in arsenic; the naturally-occurring arsenic concentrations in these surficial sediments ranged from 4.8 to 346µg/g. Dust samples from sediments used in this study had a median diameter of 4.5µm and also were a complex mixture of naturally-occurring metals, including aluminum, vanadium, chromium, manganese, iron, cobalt, copper, zinc, strontium, cesium, lead, uranium, and arsenic. Adult female B6C3F1 mice exposed via oropharyngeal aspiration to 0.01 to 100mg dust/kg body weight, four times, a week apart, for 28days, were evaluated 24h after the last exposure. Peripheral eosinophils were increased at all concentrations, serum creatinine was dose responsively increased beginning at 1.0mg/kg/day, and blood urea nitrogen was decreased at 10 and 100mg/kg/day. Antigen-specific IgM responses and natural killer cell activity were dose-responsively suppressed at 0.1mg/kg/day and above. Splenic CD4+CD25+ T cells were decreased at 0.01, 0.1, 10, and 100mg/kg/day. Antibodies against MBP, NF-68, and GFAP were selectively reduced. A no observed adverse effect level of 0.01mg/kg/day and a lowest observed adverse effect level of 0.1mg/kg/day were determined from IgM responses and natural killer cell activity, indicating that exposure to this dust, under conditions similar to our design, could affect these responses.


Subject(s)
Arsenic/toxicity , Dust/immunology , Animals , Arsenic/analysis , Blood Urea Nitrogen , Body Weight/drug effects , Complex Mixtures , Creatinine/blood , Dose-Response Relationship, Drug , Dust/analysis , Eosinophils/drug effects , Female , Immunoglobulin M/drug effects , Immunophenotyping , Killer Cells, Natural/drug effects , Mice , Neurofilament Proteins/immunology , Nevada , Organ Size/drug effects , Particle Size , Spleen/pathology
10.
J Med Chem ; 59(1): 431-47, 2016 Jan 14.
Article in English | MEDLINE | ID: mdl-26652588

ABSTRACT

Lead optimization efforts resulted in the discovery of two potent, selective, and orally bioavailable PI3Kδ inhibitors, 1 (AM-8508) and 2 (AM-9635), with good pharmacokinetic properties. The compounds inhibit B cell receptor (BCR)-mediated AKT phosphorylation (pAKT) in PI3Kδ-dependent in vitro cell based assays. These compounds which share a benzimidazole bicycle are effective when administered in vivo at unbound concentrations consistent with their in vitro cell potency as a consequence of improved unbound drug concentration with lower unbound clearance. Furthermore, the compounds demonstrated efficacy in a Keyhole Limpet Hemocyanin (KLH) study in rats, where the blockade of PI3Kδ activity by inhibitors 1 and 2 led to effective inhibition of antigen-specific IgG and IgM formation after immunization with KLH.


Subject(s)
Benzimidazoles/chemical synthesis , Benzimidazoles/pharmacology , Phosphoinositide-3 Kinase Inhibitors , Protein Kinase Inhibitors/chemical synthesis , Protein Kinase Inhibitors/pharmacology , Animals , B-Lymphocytes/drug effects , Crystallography, X-Ray , Hemocyanins/drug effects , Humans , Immunoglobulin G/drug effects , Immunoglobulin M/drug effects , Mice , Models, Molecular , Rats , Structure-Activity Relationship
11.
Int J Mol Sci ; 16(6): 14075-85, 2015 Jun 19.
Article in English | MEDLINE | ID: mdl-26101866

ABSTRACT

Hepatitis C virus (HCV) has been recognized to be both a hepato- and lymphotropic virus. HCV lymphotropism represents an essential detail in the pathogenesis of virus-related autoimmune and lymphoproliferative disorders, ranging from clonal expansion of B-cells with organ and non-organ-specific autoantibody production up to overt non-Hodgkin's lymphoma along a continuous step-by-step model of B-cell lymphomagenesis, where the intermediated mixed cryoglobulinemia could be considered as a stage of suppressible antigen-driven lymphoproliferation. The HCV long-lasting extrahepatic replicative state generates an abnormal systemic immunological response, including rheumatoid factor (RF) and cryo- and non-cryoprecipitable immune complexes, as well as clinical manifestations, comprising dermatitis, polyarthralgias and arthritis, pulmonary disease, aplastic anemia, glomerulonephritis and vasculitis. The mechanism of these extra-hepatic disorders is thought of as linked to immune complex disease, but their pathogenesis is poorly clarified. Immune-suppressive treatment could induce high-level hepatitis C viremia and impair hepatic disease. We report a female patient, whose chronic HCV-related liver cirrhosis with associated explosive, but oligosymptomatic lymphoproliferative immune response, i.e., RF beyond three thousand times the upper of normal range (unr), type II cryoglobulinemia with cryocrit 40% and monoclonal gammopathy IgM-k, has been successfully and safely treated by long-lasting (sixty-six months) combined antiviral therapy (pegylated interferon alfa and ribavirin), at moderate and tapering dose regimen, prolonged for nearly 24 months after the first viral suppression. At the last follow-up (fifty-one months), the patient was showing very-long term antiviral response, progressive decline of secondary immune activation and absence of significant side-effects. Further research is required to fully verify the real impact on therapeutic choice/regimen.


Subject(s)
Antiviral Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Cryoglobulinemia/drug therapy , Hepacivirus/immunology , Hepatitis C/complications , Immunoglobulin M/immunology , Liver Cirrhosis/virology , Arthritis, Rheumatoid/etiology , Cryoglobulinemia/etiology , Female , Humans , Immunoglobulin M/drug effects , Middle Aged , Prognosis
12.
Auris Nasus Larynx ; 42(6): 478-82, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26092312

ABSTRACT

OBJECTIVE: Transcutaneous immunization (TCI) is a novel route of vaccination through application of a topical vaccine antigen on the skin. Phosphorylcholine (PC) is a structural component of a variety of pathogens and anti-PC immune responses protect mice against invasive bacterial diseases. The purpose of the study was to examine the effect of TCI using PC in BALB/c mice. METHODS: TCI was performed in BALB/c mice using PC-keyhole limpet hemocyanin (KLH) plus cholera toxin (CT). Immunogenicity was evaluated by measuring PC-specific IgG and specific IgG1, IgG2a, IgM, IgA, and secretory IgA antibodies by ELISA. The concentrations of IL-4, IL-5, IL-10, IL-12, IL-13 and IFN-γ were also measured using ELISA for mouse. RESULTS: Six months after immunization, IgG after TCI using PC plus CT was significantly higher than in controls, but this was not found for IgA. In saliva, secretory IgA antibodies decreased with a peak level at 2-3 months. IgG1 was significantly higher than IgG2 after TCI. Production of IL-4 from CD4(+) cells was significantly higher after TCI than in controls, whereas production of IFN-γ, IL-5, IL-12 and IL-13 was not detected in either group. CONCLUSION: These results suggest that TCI using PC plus CT with BALB/c mice is a simple approach for induction of systemic and mucosal immune responses that are shifted in the Th-2 direction.


Subject(s)
Antibodies/immunology , Cytokines/immunology , Immunity, Mucosal/immunology , Phosphorylcholine/immunology , Administration, Cutaneous , Animals , Antibodies/drug effects , Cholera Toxin/immunology , Cholera Toxin/pharmacology , Cytokines/drug effects , Enzyme-Linked Immunosorbent Assay , Female , Hemocyanins/immunology , Hemocyanins/pharmacology , Immunity, Mucosal/drug effects , Immunization , Immunoglobulin A/drug effects , Immunoglobulin A/immunology , Immunoglobulin A, Secretory/drug effects , Immunoglobulin A, Secretory/immunology , Immunoglobulin G/drug effects , Immunoglobulin G/immunology , Immunoglobulin M/drug effects , Immunoglobulin M/immunology , Interferon-gamma/drug effects , Interferon-gamma/immunology , Interleukin-10/immunology , Interleukin-12/immunology , Interleukin-13/immunology , Interleukin-4/immunology , Interleukin-5/immunology , Mice , Mice, Inbred BALB C , Phosphorylcholine/pharmacology , Saliva/chemistry , Saliva/drug effects , Saliva/immunology
13.
Brain Behav Immun ; 27(1): 80-90, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23046722

ABSTRACT

Our previous work has shown that the cerebellar fastigial nucleus (FN) is involved in modulation of lymphocyte function. Herein, we investigated effect of FN γ-aminobutyric acid (GABA)-ergic projections to the hypothalamus on lymphocytes to understand pathways and mechanisms underlying cerebellar immunomodulation. By injection of Texas red dextran amine (TRDA), an anterograde tracer, into FN, we found that the TRDA-labeled fibers from the FN traveled through the superior cerebellar peduncle (SCP), crossed in decussation of SCP (XSCP), entered the hypothalamus, and primarily terminated in the lateral hypothalamic area (LHA). Further, by injecting Fluoro-Ruby (FR), a retrograde tracer, in LHA, we observed that the FR-stained fibers retrogradely passed through XSCP and reached FN. Among these FR-positive neurons in the FN, there were GABA-immunoreactive cells. We then microinjected vigabatrin, which is an inhibitor of GABA-transaminase (GABA-T) that degrades GABA, bilaterally into FN. The vigabatrin treatment increased both number of GABA-immunoreactive neurons in FN-LHA projections and GABA content in the hypothalamus. Simultaneously, vigabatrin significantly reduced concanavalin A (Con A)-induced lymphocyte proliferation, anti-sheep red blood cell (SRBC) IgM antibody level, and natural killer (NK) cell number and cytotoxicity. In support of these findings, we inhibited GABA synthesis by using 3-mercaptopropionic acid (3-MP), which antagonizes glutamic acid decarboxylase (GAD). We found that the inhibition of GABA synthesis caused changes that were opposite to those when GABA was increased with vigabatrin. These findings show that the cerebellar FN has a direct GABAergic projection to the hypothalamus and that this projection actively participates in modulation of lymphocytes.


Subject(s)
Cerebellar Nuclei/immunology , GABAergic Neurons/immunology , Hypothalamus/immunology , Lymphocytes/immunology , Nerve Fibers/immunology , 3-Mercaptopropionic Acid/pharmacology , Animals , Cell Count , Cell Proliferation/drug effects , Cerebellar Nuclei/drug effects , Chromatography, High Pressure Liquid , Cytotoxicity, Immunologic/drug effects , Cytotoxicity, Immunologic/immunology , Dextrans , Fluorescent Dyes , GABA Agents/pharmacology , GABAergic Neurons/drug effects , Glutamate Decarboxylase/antagonists & inhibitors , Hypothalamus/drug effects , Immunoglobulin M/drug effects , Immunoglobulin M/immunology , Killer Cells, Natural/drug effects , Killer Cells, Natural/immunology , Lymphocytes/drug effects , Nerve Fibers/drug effects , Rats , Rats, Sprague-Dawley , Rhodamines , T-Lymphocytes/drug effects , T-Lymphocytes/immunology , Vigabatrin/pharmacology , Xanthenes
14.
Environ Sci Pollut Res Int ; 19(6): 2300-4, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22246643

ABSTRACT

PURPOSE: The immunotoxicities of oil and its components on fish immunities have been investigated, but there is little literature on the recovery of the fish from the immune suppression. Therefore, the recovery of Japanese flounder Paralichthys olivaceus from an immunosuppressive effect due to heavy oil (HO) exposure was investigated in this study. METHODS: Fish were exposed to HO at a concentration of 0.385 g/L for 2 days, while control fish received no exposure. Seven fish were sampled at 0, 3, 7, and 14 days post-exposure. The respiratory rate was measured everyday as an indicator of the acute effect of HO exposure. Fish serum was collected and used for antibacterial activity assay against Edwardsiella tarda. Expression changes of respiratory and immune-related genes were evaluated by real-time PCR. RESULTS AND DISCUSSION: The respiratory rate was significantly increased in the HO-exposed group until 4 days post-exposure. A respiratory-related gene, ß-hemoglobin, was also significantly downregulated in the spleen both at 0 and 7 days post-exposure and kidney at 3 days post-exposure in HO-exposed fish. Immunotoxicity, including suppression of antibacterial activities and downregulation of the IgM gene, was observed in HO-exposed fish until 3 days post-exposure, but not after that time. From these results, we conclude that the fish likely return to normal status around 1 week.


Subject(s)
Flounder/immunology , Petroleum/toxicity , Water Pollutants, Chemical/toxicity , Animals , Edwardsiella tarda/immunology , Enterobacteriaceae Infections/immunology , Enterobacteriaceae Infections/veterinary , Fish Diseases/chemically induced , Fish Diseases/immunology , Fish Diseases/microbiology , Flounder/physiology , Hemoglobins/drug effects , Hemoglobins/genetics , Immunoglobulin M/drug effects , Immunoglobulin M/genetics , Muramidase/drug effects , Muramidase/genetics , Real-Time Polymerase Chain Reaction , Respiration/drug effects
15.
Eur J Oral Sci ; 119(4): 305-9, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21726292

ABSTRACT

Individuals working in a dental clinic are exposed to 2-hydroxyethyl methacrylate (HEMA). HEMA has been found to have several effects on the immune system, including acting as an adjuvant in mice and stimulating the production of human IgG1 in vitro. In this study we continued to explore the immunomodulatory properties of HEMA in mice. Mice were co-injected subcutaneously with the following: HEMA + ovalbumin (OVA) in bicarbonate buffer, OVA in bicarbonate buffer, HEMA in bicarbonate buffer, or bicarbonate buffer alone. Mice immunized with OVA were killed 2 wk after a booster injection. Mice exposed to HEMA only were killed 6 d after the last injection with HEMA. Serum and spleens were collected. The activities of anti-OVA IgG and anti-OVA IgM were determined using ELISAs, as was the in vitro production of tumour necrosis factor-α (TNF-α) and interleukin-6 (IL-6) by splenocytes after 2 d of incubation. Splenocyte proliferation was analyzed using [(3) H]thymidine decomposition. Mice exposed twice to HEMA in vivo had a higher baseline and a higher concanavalin A-stimulated proliferation of splenocytes, and produced less TNF-α in relation to IL-6, compared with controls. Immunization of mice with OVA/HEMA resulted in a higher anti-OVA IgG activity, relative to anti-OVA IgM activity, compared with controls. In conclusion, HEMA has selective effects on cytokine and antibody production in mice.


Subject(s)
Dental Materials/pharmacology , Immunoglobulin G/drug effects , Immunoglobulin M/drug effects , Methacrylates/pharmacology , Animals , Bicarbonates , Buffers , Cell Proliferation/drug effects , Concanavalin A/pharmacology , Immunization , Immunoglobulin G/biosynthesis , Immunoglobulin M/biosynthesis , Immunologic Factors/immunology , Immunologic Factors/pharmacology , Injections, Subcutaneous , Interleukin-6/analysis , Male , Mice , Mice, Inbred BALB C , Mitogens/pharmacology , Ovalbumin/immunology , Specific Pathogen-Free Organisms , Spleen/cytology , Spleen/drug effects , Spleen/immunology , Tumor Necrosis Factor-alpha/analysis
16.
J Indian Med Assoc ; 108(2): 92-3, 2010 Feb.
Article in English | MEDLINE | ID: mdl-20839565

ABSTRACT

The effect of zinc supplementation on the serum level of IgA, IgG, IgM mycospecific immunoglobulins in tuberculosis patients alongwith normal control and disease control subjects were studied. It was observed that with antituberculous drugs for one month (without zinc supplementation), the serum level of immunoglobulins in tuberculosis subjects although decreased significantly, but with zinc supplementation along with antituberculous drugs for one month the decrease in the level of immunoglobulins in serum was more significant. This may be attributed to the effect of zinc supplementation favouring the normal compartmentalisation state of iron and also to the immunomodulatory effect of zinc.


Subject(s)
Immunoglobulins/blood , Mycobacterium tuberculosis/drug effects , Tuberculosis/blood , Tuberculosis/drug therapy , Zinc/pharmacology , Case-Control Studies , Enzyme-Linked Immunosorbent Assay , Humans , Immunoglobulin A/blood , Immunoglobulin A/drug effects , Immunoglobulin G/blood , Immunoglobulin G/drug effects , Immunoglobulin M/blood , Immunoglobulin M/drug effects , Immunoglobulins/drug effects , Mycobacterium tuberculosis/immunology , Tuberculosis/immunology
17.
J Dent Res ; 89(12): 1461-4, 2010 Dec.
Article in English | MEDLINE | ID: mdl-20811070

ABSTRACT

UNLABELLED: We have previously shown that the resin monomer 2-hydroxyethylmethacrylate (HEMA) affects mouse B-lymphocyte activity, leading to increased IgG1 antibody production in vivo. In the present study, we tested, in vitro, the hypothesis that HEMA also affects human B-lymphocyte activity. The in vitro production of IgG1, IgM, and IgA in supernatants from purified human CD19+ B-lymphocyte cultures, containing different concentrations of HEMA, was assayed with ELISA. Proliferation was measured by [methyl-(3)H] thymidine incorporation. Of the different HEMA concentrations used, the lower concentrations caused a significant increase in IgG1 production, but not in IgM or IgA production, in vitro. The lower HEMA concentrations did not significantly change B-cell proliferation. At the highest concentration, HEMA significantly suppressed IgG1 and IgM production, as well as B-cell proliferation, in vitro. In conclusion, HEMA can, at certain concentrations, selectively enhance human B-lymphocyte IgG1 production. ABBREVIATIONS: 2-hydroxyethylmethacrylate (HEMA), Dulbecco's Modified Eagle's Medium supplemented with heat-inactivated fetal bovine serum, gentamycin, penicillin, and streptomycin (D-MEM++++), Enzyme-linked Immuno-sorbent Assay (ELISA), phosphate-buffered saline (PBS), ovalbumin (OVA), pokeweed mitogen (PWM), counts per minute (CPM).


Subject(s)
B-Lymphocytes/drug effects , Dental Materials/pharmacology , Immunoglobulin G/drug effects , Methacrylates/pharmacology , Antigens, CD19/immunology , B-Lymphocytes/classification , B-Lymphocytes/immunology , Cell Culture Techniques , Cell Proliferation/drug effects , Cells, Cultured , Humans , Immunoglobulin A/analysis , Immunoglobulin A/drug effects , Immunoglobulin G/analysis , Immunoglobulin M/analysis , Immunoglobulin M/drug effects , Materials Testing , Radiopharmaceuticals , Thymidine/metabolism , Tritium
18.
East Mediterr Health J ; 16(3): 308-12, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20795446

ABSTRACT

This retrospective review of hospital records analysed pregnancy outcome with 2 different treatments for women with recurrent miscarriage diagnosed with antiphospholipid syndrome in the index pregnancy. Of 64 women, 29 had received aspirin and 35 aspirin plus heparin. Pregnancy-induced hypertension, prematurity, intrauterine growth restriction and neonatal death were considered as maternal and fetal complications. There were no significant differences in antenatal and maternal complications between the groups. HOwever, there were significant differences in mean anticardiolipin IgG antibody levels. Aspirin alone or in combination with parin was equally efficacious in women with antiphospholipid syndrome and recurrent miscarriage.


Subject(s)
Antiphospholipid Syndrome/drug therapy , Aspirin/therapeutic use , Fibrinolytic Agents/therapeutic use , Heparin/therapeutic use , Pregnancy Complications/drug therapy , Pregnancy Outcome/epidemiology , Adult , Antibodies, Anticardiolipin/blood , Antibodies, Anticardiolipin/drug effects , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/complications , Antiphospholipid Syndrome/immunology , Aspirin/pharmacology , Chi-Square Distribution , Drug Therapy, Combination , Female , Fibrinolytic Agents/pharmacology , Heparin/pharmacology , Humans , Immunoglobulin G/blood , Immunoglobulin G/drug effects , Immunoglobulin M/blood , Immunoglobulin M/drug effects , Pakistan/epidemiology , Pregnancy , Pregnancy Complications/blood , Pregnancy Complications/immunology , Retrospective Studies , Treatment Outcome
19.
Am J Respir Crit Care Med ; 182(11): 1352-61, 2010 Dec 01.
Article in English | MEDLINE | ID: mdl-20639443

ABSTRACT

RATIONALE: Sulfur mustard (SM) is a frequently used chemical warfare agent, even in modern history. SM inhalation causes significant respiratory tract injury, with early complications due to airway obstructive bronchial casts, akin to those seen after smoke inhalation and in single-ventricle physiology. This process with SM is poorly understood because animal models are unavailable. OBJECTIVES: To develop a rat inhalation model for airway obstruction with the SM analog 2-chloroethyl ethyl sulfide (CEES), and to investigate the pathogenesis of bronchial cast formation. METHODS: Adult rats were exposed to 0, 5, or 7.5% CEES in ethanol via nose-only aerosol inhalation (15 min). Airway microdissection and confocal microscopy were used to assess cast formation (4 and 18 h after exposure). Bronchoalveolar lavage fluid (BALF) retrieval and intravascular dye injection were done to evaluate vascular permeability. MEASUREMENTS AND MAIN RESULTS: Bronchial casts, composed of abundant fibrin and lacking mucus, occluded dependent lobar bronchi within 18 hours of CEES exposure. BALF contained elevated concentrations of IgM, protein, and fibrin. Accumulation of fibrin-rich fluid in peribronchovascular regions (4 h) preceded cast formation. Monastral blue dye leakage identified bronchial vessels as the site of leakage. CONCLUSIONS: After CEES inhalation, increased permeability from damaged bronchial vessels underlying damaged airway epithelium leads to the appearance of plasma proteins in both peribronchovascular regions and BALF. The subsequent formation of fibrin-rich casts within the airways then leads to airways obstruction, causing significant morbidity and mortality acutely after exposure.


Subject(s)
Airway Obstruction/chemically induced , Bronchi/blood supply , Bronchi/drug effects , Chemical Warfare Agents/toxicity , Mustard Gas/toxicity , Animals , Blotting, Western , Bronchoalveolar Lavage Fluid , Capillary Permeability/drug effects , Disease Models, Animal , Fibrin/drug effects , Immunoglobulin M/drug effects , Inhalation Exposure , Male , Microdissection , Microscopy, Confocal , Rats , Rats, Sprague-Dawley
20.
J Gastroenterol ; 44(11): 1133-9, 2009.
Article in English | MEDLINE | ID: mdl-19626266

ABSTRACT

BACKGROUND: Autoimmune pancreatitis (AIP) is a rare type of chronic pancreatitis caused by an autoimmune abnormality. It is well known that high serum concentrations of IgG4 are helpful for making a diagnosis of AIP; however, it is unclear whether there are abnormalities in the production of other immunoglobulins in AIP. METHODS: We examined the immune condition of AIP patients before and after glucocorticoid treatment, focusing on serum levels of IgG, IgG4, IgM and IgA, and compared the results with those in other hepato-pancreatic diseases, such as autoimmune hepatitis, primary biliary cirrhosis, chronic pancreatitis and pancreatic carcinoma. RESULTS: IgM and IgA were decreased in patients with untreated AIP. IgM and IgG or IgG4 were negatively correlated in patients with AIP. The ratios of IgG to IgM and IgG to IgA in patients with AIP were significantly increased compared with the other diseases. The diagnostic sensitivity of IgG to IgM and IgG to IgA was 0.800 and 0.950, and the specificity of each ratio was 0.703 and 0.728, respectively, in the differentiation of AIP from the other diseases. IgM was not significantly changed after glucocorticoid treatment in the patients with AIP, while IgG, IgG4 and IgA decreased. CONCLUSIONS: The ratios of IgG to IgM and IgG to IgA may serve as novel diagnostic markers to differentiate AIP from other hepato-pancreatic diseases. Furthermore, low concentrations of IgM and IgA may be involved in the pathogenesis of AIP.


Subject(s)
Autoimmune Diseases/immunology , Immunoglobulin A/blood , Immunoglobulin M/blood , Pancreatitis, Chronic/immunology , Aged , Autoimmune Diseases/diagnosis , Autoimmune Diseases/drug therapy , Female , Glucocorticoids/therapeutic use , Humans , Immunoglobulin A/drug effects , Immunoglobulin G/blood , Immunoglobulin G/drug effects , Immunoglobulin M/drug effects , Liver Diseases/immunology , Male , Middle Aged , Pancreatic Diseases/immunology , Pancreatitis, Chronic/diagnosis , Pancreatitis, Chronic/drug therapy , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL